CancerNCT06275854
YASU Research Registry: For Young Adults With Cancer
An observational study of Cancer and Leukemia, run by Young Adult Survivors United at 1 site in United States.
Trial summary
The goal of this observational research registry is to learn about health, wellbeing, and needs of survivors of young adult cancer (diagnosed between the ages of 18 and 39). The main question[s] it aims to understand are: What are the levels of depression, anxiety, social support, and financial distress Determine… Read more about this study
- Who is it for?
- Ages 18 years and older
- How many people
- 192 participants
- Where
- 1 siteUnited States
- Study dates
- 3 Feb 2025to 30 Sep 2025
- How long will I take part?
- 10 Years
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Any young adult diagnosed with cancer between the ages of 18 and 39 willing to register on the YASU website and consents to participation in the research registry.
Who may be able to join
- Cancer diagnosis received between the ages of 18 and 39.
- Able to speak and read English
Who cannot join
- Inability to provide consent (such as neurological illness or mental incapacity)
- Has not registered as a member of YASU
Trial locations and contacts
1 site in 1 country.
United States1 site
Young Adult Survivors United
Wexford, Pennsylvania, 15090
About this study
Official title: Young Adult Survivors United Cancer Research Registry
The goal of this observational research registry is to learn about health, wellbeing, and needs of survivors of young adult cancer (diagnosed between the ages of 18 and 39). The main question[s] it aims to understand are:
- What are the levels of depression, anxiety, social support, and financial distress
- Determine effectiveness of YASU programming by measuring changes over time
With this registry, the investigators also plan to identify survivors who may be eligible for participation in future research studies pertaining to young adult cancer.
Participants will be asked to complete electronic surveys every 6 to 12 months during participation in the registry.
Read the detailed description
The study will be conducted online.
- Conditions
- Cancer, Leukemia, Sarcoma, Germ Cell Cancer, Lymphoma, Colorectal Cancer
- Keywords
- young adult cancer
- Medical subject headings
- Neoplasms, Leukemia, Sarcoma, Neoplasms, Germ Cell and Embryonal, Lymphoma, Colorectal Neoplasms, Melanoma, Breast Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
Anxiety
General Anxiety Disorder-7 (GAD-7). Scores range from 0-21 with higher scores indicating higher levels of anxiety.
Measured: enrollment in registry, 6 months later, yearly until death
Depressive symptoms
Patient Health Questionnaire- 9 (PHQ-9) Scores range from 0-27, with higher scores indicating more depressive symptoms.
Measured: enrollment in registry, 6 months later, yearly until death
Social Support
MOS Social Support Survey Instrument The survey consists of four separate social support subscales and an overall functional social support index. A higher score for an individual scale or for the overall support index indicates more support.
MOS Social Support Survey Instrument
Measure of Social Support Survey Instrument
Measured: enrollment in registry, 6 months later, yearly until death
Financial Toxicity
COST: A FACIT Measure of Financial Toxicity (COST - FACIT (Ver 2)) Scores range from 0-44. The higher the score, the better the Financial Well-Being
Measured: enrollment in registry, 6 months later, yearly until death
Needs Assessment
AYA Psycho-Oncology Screening Tool (AYA-POST) There is no scoring required for this tool.
Measured: enrollment in registry
Secondary outcomes (1)
Name, address, email, phone number
Contact information if willing to be alerted about future research
Measured: enrollment in registry
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Feb 2024
- Study start3 Feb 2025
- Primary completion30 Sep 2025
- Study completion30 Sep 2025
Why it stopped: Sponsoring organization no longer desired to recruit/maintain registry
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 192 participants (actual)
- Target duration
- 10 Years
Sponsor and investigators
- Lead sponsor
- Young Adult Survivors United
- Sponsor type
- University, hospital or other
- Collaborators
- Staunton Farm Foundation, Elsie H. Hillman Foundation
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06275854
- Sponsor's protocol ID
- 22265
- Status last verified
- Oct 2025
- First submitted
- 22 Jan 2024
- Last updated
- 14 Oct 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 14 Oct 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Young Adult Survivors United Cancer Research Registry
- ClinicalTrials.gov ID
- NCT06275854
- Acronym / sponsor ID
- 22265
- Conditions
- Cancer, Leukemia, Sarcoma, Germ Cell Cancer, Lymphoma, Colorectal Cancer
- Keywords
- young adult cancer
- Study type
- Observational
- Recruitment status
- TerminatedReason stopped: Sponsoring organization no longer desired to recruit/maintain registry
- Enrolment
- 192 participants (actual)
- Lead sponsor
- Young Adult Survivors UnitedUniversity, hospital or other
- Collaborators
- Staunton Farm Foundation, Elsie H. Hillman Foundation
- Study start
- 3 Feb 2025 (actual)
- Primary completion
- 30 Sep 2025 (actual)
- Study completion
- 30 Sep 2025 (actual)
- First posted
- 23 Feb 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational research registry is to learn about health, wellbeing, and needs of survivors of young adult cancer (diagnosed between the ages of 18 and 39). The main question[s] it aims to understand are:
- What are the levels of depression, anxiety, social support, and financial distress
- Determine effectiveness of YASU programming by measuring changes over time
With this registry, the investigators also plan to identify survivors who may be eligible for participation in future research studies pertaining to young adult cancer.
Participants will be asked to complete electronic surveys every 6 to 12 months during participation in the registry.
Detailed description
The study will be conducted online.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 10 Years
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Any young adult diagnosed with cancer between the ages of 18 and 39 willing to register on the YASU website and consents to participation in the research registry.
Key inclusion criteria (2 listed)
- Cancer diagnosis received between the ages of 18 and 39.
- Able to speak and read English
Key exclusion criteria (2 listed)
- Inability to provide consent (such as neurological illness or mental incapacity)
- Has not registered as a member of YASU
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Anxiety
Time frame: enrollment in registry, 6 months later, yearly until death
General Anxiety Disorder-7 (GAD-7). Scores range from 0-21 with higher scores indicating higher levels of anxiety.
Depressive symptoms
Time frame: enrollment in registry, 6 months later, yearly until death
Patient Health Questionnaire- 9 (PHQ-9) Scores range from 0-27, with higher scores indicating more depressive symptoms.
Social Support
Time frame: enrollment in registry, 6 months later, yearly until death
MOS Social Support Survey Instrument The survey consists of four separate social support subscales and an overall functional social support index. A higher score for an individual scale or for the overall support index indicates more support. MOS Social Support Survey Instrument Measure of Social Support Survey Instrument
Financial Toxicity
Time frame: enrollment in registry, 6 months later, yearly until death
COST: A FACIT Measure of Financial Toxicity (COST - FACIT (Ver 2)) Scores range from 0-44. The higher the score, the better the Financial Well-Being
Needs Assessment
Time frame: enrollment in registry
AYA Psycho-Oncology Screening Tool (AYA-POST) There is no scoring required for this tool.
1 secondary outcome
Name, address, email, phone number
Time frame: enrollment in registry
Results and safety
The study was stopped early (reason given: Sponsoring organization no longer desired to recruit/maintain registry). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Oct 2025.
- Individual participant dataSharing planned: Yes
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer and Leukemia, run by Young Adult Survivors United at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 14 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Sponsoring organization no longer desired to recruit/maintain registry). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Anxiety (time frame: enrollment in registry, 6 months later, yearly until death). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Oct 2025; AzTrials last refreshed its copy on 7 Nov 2026.